Business Expansion and Acquisitions - Veracyte reported a significant expansion in its genomic testing menu with the acquisition of Decipher Biosciences, enhancing capabilities in urologic cancers [122]. - The acquisition of HalioDx in August 2021 allowed Veracyte to manufacture its own IVD test kits, strengthening its position in immuno-oncology [123]. - The integration of acquired assets from Decipher Biosciences and HalioDx may impact revenue growth and operational results as functions are consolidated [130]. Financial Performance - Total revenue for the three months ended June 30, 2022, was $72.864 million, representing a 32% increase compared to $55.105 million in the same period of 2021 [155]. - Testing revenue increased by 18% to $59.718 million for the three months ended June 30, 2022, compared to $50.793 million in the same period of 2021 [155]. - Biopharmaceutical and other revenue surged by 518% to $10.038 million for the three months ended June 30, 2022, compared to $1.624 million in the same period of 2021 [155]. - The company reported a net loss of $9.532 million for the three months ended June 30, 2022, a 5% increase from a net loss of $9.038 million in the same period of 2021 [155]. - The company recorded a net loss of $24.0 million for the six months ended June 30, 2022, with an accumulated deficit of $381.2 million as of the same date [174]. Testing Volume and Revenue - Total test volume increased by 19% to 24,904 tests for the three months ended June 30, 2022, compared to 20,856 tests in the same period of 2021 [155]. - Revenue increased by $17.8 million for the three months ended June 30, 2022, primarily due to a $8.9 million increase in testing revenue driven by a 19% volume increase in diagnostic tests [157]. - For the six months ended June 30, 2022, revenue increased by $48.8 million, with a $31.8 million increase in testing revenue driven by a 40% volume increase in diagnostic tests [158]. Expenses and Costs - Research and development expenses rose by 50% to $9.377 million for the three months ended June 30, 2022, compared to $6.249 million in the same period of 2021 [155]. - Selling and marketing expenses increased by 22% to $24.001 million for the three months ended June 30, 2022, compared to $19.662 million in the same period of 2021 [155]. - General and administrative expenses increased by $4.3 million (28%) for the three months ended June 30, 2022, compared to the same period in 2021, primarily due to compensation related to the acquisition of HalioDx and headcount additions [168]. - Compensation expense in research and development increased by 44% for the three months ended June 30, 2022, reflecting higher headcount and annual compensation increases [163]. Cash Flow and Financial Position - Cash used in operating activities for the six months ended June 30, 2022, was $9.2 million, a significant decrease from $38.7 million in the same period in 2021 [182]. - Cash used in investing activities for the six months ended June 30, 2022, was $11.8 million, compared to $574.1 million in the same period in 2021, which included the acquisition of Decipher Biosciences [186]. - Cash provided by financing activities for the six months ended June 30, 2022, was $1.9 million, a sharp decline from $592.9 million in the same period in 2021, which was primarily from a public offering [188]. - The company expects its existing cash and cash equivalents of $164.0 million as of June 30, 2022, to be sufficient to meet anticipated cash requirements for at least the next 12 months [175]. Market and Operational Challenges - The company has faced challenges in test volumes due to COVID-19, particularly affecting tests that require hospital procedures, such as Percepta and Envisia [125]. - Veracyte's Decipher Prostate test remained resilient during the pandemic, primarily due to its customer base being community-based urology practices [125]. - The company is facing inflation headwinds in compensation, travel, and supply costs, but does not believe inflation has materially affected its business or financial condition [194]. Research and Development - The company expects significant research and development expenses as it continues to invest in developing additional products and evaluating various platforms [148]. - The operations of HalioDx contributed approximately $8.8 million to the cost of biopharmaceutical and other revenue for the six months ended June 30, 2022 [162]. - Research and development expenses rose by $3.1 million, or 50%, for the three months ended June 30, 2022, with HalioDx operations contributing approximately $2.2 million to this increase [163]. Reimbursement and Revenue Recognition - Revenue growth is contingent on securing broader reimbursement from third-party payers and expanding the base of prescribing physicians [129]. - The average reimbursement rates for tests are subject to change based on payer coverage decisions and contractual agreements [137]. - Veracyte's testing revenue is recognized upon completion of tests, with billing occurring at the time results are delivered [133].

Veracyte, Inc. (NASDAQ:VCYT) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Tina Nova - President of CLIA Business Giulia Kennedy - Global Chief Scientific Officer and Chief Medical Officer Conference Call Participants Brian Weinstein - William Blair Puneet Souda - SVB Securities Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Andrew Coope ...

(veracyte. Q1 2022 Business & Financial Presentation May 3, 2022 Disclaimer This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue and other financial and operating results for 2022 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, LymphMark, Decipher Prostate, Percepta Nasal Swab, Percepta Genomic Atlas and Decipher Bladder tests and prod ...

Veracyte, Inc. (NASDAQ:VCYT) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Giulia Kennedy – Chief Scientific & Medical Officer Tina Nova – General Manager of Thyroid & Urologic Cancer Sheila Goldman – Director of Investor Relations Conference Call Participants Brian Weinstein – William Blair David Hein – Goldman Sachs Mason Carrico – Stephens Inc. Tejas Savant – Morgan Stanley Paul Knight – KeyBa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of (I ...

veracyte. Q4 and Full Year 2021 Business & Financial Presentation February 28, 2022 Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue and other financial and operating results for 2022 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, LymphMark, Decipher Prostate, Percepta Nasal Swab, Percepta Genomic Atlas ...

Veracyte, Inc. (NASDAQ:VCYT) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Tracy Morris - VP of Corporate Communications & IR Marc Stapley - CEO Rebecca Chambers - CFO Tina Nova - General Manager of Thyroid & Urologic Cancer Giulia Kennedy - Chief Scientific & Medical Officer Conference Call Participants Brian Weinstein - William Blair Matt Sykes - Goldman Sachs Puneet Souda - SVB Leerink Mike Matson - Needham & Company Mason Carrico - Stephens Inc. Travis Broadhurst - L ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission File Number 001-36156 VERACYTE, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 20-5455398 (I.R.S. Employer Identification Number) Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSU ...

veracyte. Third Quarter 2021 Performance Business & Financial Presentation November 9, 2021 Forward-Looking Statements This presentation contains statements that are not historical and that are based on our beliefs and assumptions and on information currently available to us. These statements constitute forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to known and unknown risks, uncerta ...

Call Start: 16:30 January 1, 0000 5:23 PM ET Veracyte, Inc. (NASDAQ:VCYT) Q3 2021 Earnings Conference Call November 9, 2021 16:30 ET Company Participants Tracy Morris - Vice President of Corporate Communications & Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Tina Nova - General Manager of Thyroid & Urologic Cancer Giulia Kennedy - Chief Scientific & Medical Officer Conference Call Participants Puneet Souda - SVB Leerink Matt Sykes - Goldman Sachs Mike ...